佐力藥業(300181.SZ):2022年度烏靈系列營業收入達10.92億元
格隆匯6月15日丨佐力藥業(300181.SZ)召開線上會議,就“烏靈系列的收入佔比?烏靈膠囊適用人羣的平均年齡是多少?”
公司回覆稱,烏靈系列中收入最主要的還是烏靈膠囊和靈澤片。靈蓮花顆粒因為沒有進入基藥和醫保目錄,所以收入佔比較小。2022年度烏靈系列營業收入達10.92億元,靈澤片在2021年含税收入突破1億元,去年收入增長68.42%,收入大概是1億多,其餘的營收來自烏靈膠囊。2、目前我國存在睡眠障礙的人口超3億人,失眠和焦慮抑鬱人羣本身年齡跨度就很大,烏靈膠囊作為烏靈菌粉單方製劑,安全性很高,而且可以與其他藥物聯合使用,病人依從性高。烏靈膠囊適用人羣的年齡分佈比較寬泛,從中學生到老年人都可以使用。此外,老年人使用烏靈膠囊就更加普遍了,公司正在開展烏靈膠囊針對治療老年痴呆方向(AD)的二次開發,也在關注老年輕度認知功能障礙(MCI)方面的研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.